[Cutaneous pseudolymphoma caused by carbamazepine]. 1998

M d'Incan, and M L Mouillet, and H Roger, and M C Ferrier, and J P Buono, and P Déchelotte, and Y J Bignon, and P Souteyrand
Service de Dermatologie-Vénéréologie, Hôtel-Dieu, Clermont-Ferrand.

BACKGROUND Drug-induced cutaneous pseudolymphomas are poorly reported. They clinically and pathologically mimic malignant lymphomas but their evolution is benign after drug withdrawal. METHODS We herein reported a case of carbamazepine++-induced pseudolymphoma in a 30 year-old woman of particular interest because of the paucity of clinical symptoms (only six papules of less than one centimetre each). CONCLUSIONS Phenytoins, carbamazepine++, barbiturates and ACE inhibitors are the main drugs inducing cutaneous pseudolymphomas. These usually mimic T-cell lymphomas. The clinical spectrum of cutaneous pseudolymphomas is broad including severe aspects, such as erythroderma or tumoral eruption and benign appearing one as in our case. Drug investigation is mandatory for each patient with lymphoma appearing cutaneous infiltrates because dramatic and definitive healing of the lesion is always expected in case of pseudolymphoma.

UI MeSH Term Description Entries
D002220 Carbamazepine A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties. Amizepine,Carbamazepine Acetate,Carbamazepine Anhydrous,Carbamazepine Dihydrate,Carbamazepine Hydrochloride,Carbamazepine L-Tartrate (4:1),Carbamazepine Phosphate,Carbamazepine Sulfate (2:1),Carbazepin,Epitol,Finlepsin,Neurotol,Tegretol
D003875 Drug Eruptions Adverse cutaneous reactions caused by ingestion, parenteral use, or local application of a drug. These may assume various morphologic patterns and produce various types of lesions. Dermatitis Medicamentosa,Dermatitis, Adverse Drug Reaction,Maculopapular Drug Eruption,Maculopapular Exanthem,Morbilliform Drug Reaction,Morbilliform Exanthem,Drug Eruption,Drug Eruption, Maculopapular,Drug Eruptions, Maculopapular,Drug Reaction, Morbilliform,Drug Reactions, Morbilliform,Eruption, Drug,Eruption, Maculopapular Drug,Eruptions, Drug,Eruptions, Maculopapular Drug,Exanthem, Maculopapular,Exanthem, Morbilliform,Exanthems, Maculopapular,Exanthems, Morbilliform,Maculopapular Drug Eruptions,Maculopapular Exanthems,Morbilliform Drug Reactions,Morbilliform Exanthems,Reaction, Morbilliform Drug,Reactions, Morbilliform Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012871 Skin Diseases Diseases involving the DERMIS or EPIDERMIS. Dermatoses,Skin and Subcutaneous Tissue Disorders,Dermatosis,Skin Disease
D013909 Thorax The upper part of the trunk between the NECK and the ABDOMEN. It contains the chief organs of the circulatory and respiratory systems. (From Stedman, 25th ed) Chest,Thoraces,Chests,Thorace
D019310 Pseudolymphoma A group of disorders having a benign course but exhibiting clinical and histological features suggestive of malignant lymphoma. Pseudolymphoma is characterized by a benign infiltration of lymphoid cells or histiocytes which microscopically resembles a malignant lymphoma. (From Dorland, 28th ed & Stedman, 26th ed) Hyperplasia, Reactive Lymphoid,Lymphocytoma,Lymphoid Hyperplasia, Reactive,Hyperplasias, Reactive Lymphoid,Lymphocytomas,Lymphoid Hyperplasias, Reactive,Pseudolymphomas,Reactive Lymphoid Hyperplasia,Reactive Lymphoid Hyperplasias

Related Publications

M d'Incan, and M L Mouillet, and H Roger, and M C Ferrier, and J P Buono, and P Déchelotte, and Y J Bignon, and P Souteyrand
May 2013, Saudi medical journal,
M d'Incan, and M L Mouillet, and H Roger, and M C Ferrier, and J P Buono, and P Déchelotte, and Y J Bignon, and P Souteyrand
June 2001, The British journal of dermatology,
M d'Incan, and M L Mouillet, and H Roger, and M C Ferrier, and J P Buono, and P Déchelotte, and Y J Bignon, and P Souteyrand
September 2018, Journal of the European Academy of Dermatology and Venereology : JEADV,
M d'Incan, and M L Mouillet, and H Roger, and M C Ferrier, and J P Buono, and P Déchelotte, and Y J Bignon, and P Souteyrand
January 2006, Revista de neurologia,
M d'Incan, and M L Mouillet, and H Roger, and M C Ferrier, and J P Buono, and P Déchelotte, and Y J Bignon, and P Souteyrand
September 1997, Indian pediatrics,
M d'Incan, and M L Mouillet, and H Roger, and M C Ferrier, and J P Buono, and P Déchelotte, and Y J Bignon, and P Souteyrand
November 1993, Contact dermatitis,
M d'Incan, and M L Mouillet, and H Roger, and M C Ferrier, and J P Buono, and P Déchelotte, and Y J Bignon, and P Souteyrand
January 1995, La Revue de medecine interne,
M d'Incan, and M L Mouillet, and H Roger, and M C Ferrier, and J P Buono, and P Déchelotte, and Y J Bignon, and P Souteyrand
January 1998, Ryoikibetsu shokogun shirizu,
M d'Incan, and M L Mouillet, and H Roger, and M C Ferrier, and J P Buono, and P Déchelotte, and Y J Bignon, and P Souteyrand
June 1978, The Journal of dermatologic surgery and oncology,
M d'Incan, and M L Mouillet, and H Roger, and M C Ferrier, and J P Buono, and P Déchelotte, and Y J Bignon, and P Souteyrand
February 1996, Journal of the Indian Medical Association,
Copied contents to your clipboard!